Progeny 3, Inc. - 14 Feb 2025 Form 3 Insider Report for ACUREN CORP (TIC)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
14 Feb 2025, 18:35:33 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Chris Hemingway, Co-Chief Investment Officer

Key filing fact

Progeny 3, Inc. filed Form 3 for ACUREN CORP (TIC) on 14 Feb 2025.

Key facts

  • This page summarizes Progeny 3, Inc.'s Form 3 filing for ACUREN CORP (TIC).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Feb 2025, 18:35.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TIC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
15,000,000
Date
14 Feb 2025
Ownership
See footnote
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares are held of record by P3-EQ, LLC. The reporting person is the managing member of P3-EQ, LLC and has voting control over all 15,000,000 shares. Jon Hemingway is the sole shareholder of Progeny 3, Inc. and may be deemed to have beneficial ownership of the shares held by P3-EQ, LLC.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .